Dafna Capital Management LLC Biocryst Pharmaceuticals Inc Transaction History

Dafna Capital Management LLC

$331 Million
Q1 2025

A detailed history of Dafna Capital Management LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Dafna Capital Management LLC holds 558,255 shares of BCRX stock, worth $5.91 Million. This represents 1.26% of its overall portfolio holdings.

Number of Shares

558,255

Previous 667,000 16.3%

Holding current value

$5.91 Million

Previous $5.02 Million 16.53%

% of portfolio

1.26%

Previous 1.36%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$7.06 - $9.39 $767,739 - $1.02 Million	-108,745 Reduced 16.3%	558,255 $4.19 Million
Q3 2024 Nov 14, 2024	SELL	$6.41 - $8.69 $240,375 - $325,875	-37,500 Reduced 5.32%	667,000 $5.07 Million
Q2 2024 Aug 14, 2024	SELL	$4.13 - $6.79 $20,650 - $33,950	-5,000 Reduced 0.7%	704,500 $4.35 Million
Q4 2023 Feb 14, 2024	BUY	$4.98 - $6.77 $286,350 - $389,275	57,500 Added 8.82%	709,500 $4.25 Million
Q3 2023 Nov 14, 2023	BUY	$6.71 - $7.92 $556,930 - $657,360	83,000 Added 14.59%	652,000 $4.62 Million
Q2 2023 Aug 14, 2023	BUY	$6.96 - $8.81 $121,800 - $154,175	17,500 Added 3.17%	569,000 $4.01 Million
Q1 2023 May 15, 2023	BUY	$7.94 - $11.84 $2.39 Million - $3.56 Million	300,500 Added 119.72%	551,500 $4.6 Million
Q4 2022 Feb 14, 2023	BUY	$10.5 - $14.2 $2.64 Million - $3.56 Million	251,000 New	251,000 $2.88 Million
Q4 2020 Feb 16, 2021	SELL	$3.37 - $8.61 $2.52 Million - $6.45 Million	-749,051 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$3.43 - $5.53 $17,150 - $27,650	5,000 Added 0.67%	749,051 $2.57 Million
Q2 2020 Aug 14, 2020	BUY	$1.9 - $5.61 $503,500 - $1.49 Million	265,000 Added 55.32%	744,051 $3.55 Million
Q1 2020 May 15, 2020	SELL	$1.6 - $4.11 $56,000 - $143,850	-35,000 Reduced 6.81%	479,051 $958,000
Q4 2019 Feb 14, 2020	BUY	$1.59 - $3.45 $48,754 - $105,787	30,663 Added 6.34%	514,051 $1.77 Million
Q3 2019 Nov 14, 2019	BUY	$2.5 - $3.73 $181,250 - $270,425	72,500 Added 17.64%	483,388 $1.39 Million
Q2 2019 Aug 14, 2019	SELL	$2.91 - $9.15 $254,703 - $800,872	-87,527 Reduced 17.56%	410,888 $1.56 Million
Q1 2019 May 15, 2019	BUY	$7.38 - $9.72 $250,920 - $330,480	34,000 Added 7.32%	498,415 $4.06 Million
Q4 2018 Feb 14, 2019	SELL	$6.51 - $9.6 $1.22 Million - $1.8 Million	-187,671 Reduced 28.78%	464,415 $3.75 Million
Q3 2018 Nov 14, 2018	BUY	$5.52 - $7.99 $261,835 - $378,997	47,434 Added 7.84%	652,086 $4.98 Million
Q2 2018 Aug 13, 2018	SELL	$4.6 - $6.52 $1.7 Million - $2.41 Million	-370,000 Reduced 37.96%	604,652 $3.47 Million
Q1 2018 May 15, 2018	SELL	$4.35 - $5.82 $950,805 - $1.27 Million	-218,576 Reduced 18.32%	974,652 $4.65 Million
Q3 2017 Nov 14, 2017	BUY	$4.1 - $5.97 $4.89 Million - $7.12 Million	1,193,228	1,193,228 $6.25 Million

Others Institutions Holding BCRX

# of Institutions

292

Shares Held

177M

Call Options Held

721K

Put Options Held

489K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.97B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dafna Capital Management LLC with notifications on news.

Account

Dafna Capital Management LLC Biocryst Pharmaceuticals Inc Transaction History